174 related articles for article (PubMed ID: 26918322)
21. Functional properties and substrate characterization of human CYP26A1, CYP26B1, and CYP26C1 expressed by recombinant baculovirus in insect cells.
Helvig C; Taimi M; Cameron D; Jones G; Petkovich M
J Pharmacol Toxicol Methods; 2011; 64(3):258-63. PubMed ID: 21906690
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and CYP26A1 inhibitory activity of novel methyl 3-[4-(arylamino)phenyl]-3-(azole)-2,2-dimethylpropanoates.
Gomaa MS; Lim AS; Lau SC; Watts AM; Illingworth NA; Bridgens CE; Veal GJ; Redfern CP; Brancale A; Armstrong JL; Simons C
Bioorg Med Chem; 2012 Oct; 20(20):6080-8. PubMed ID: 22989911
[TBL] [Abstract][Full Text] [Related]
23. The retinoic acid hydroxylase Cyp26a1 has minor effects on postnatal vitamin A homeostasis, but is required for exogenous
Zhong G; Hogarth C; Snyder JM; Palau L; Topping T; Huang W; Czuba LC; LaFrance J; Ghiaur G; Isoherranen N
J Biol Chem; 2019 Jul; 294(29):11166-11179. PubMed ID: 31167781
[TBL] [Abstract][Full Text] [Related]
24. Regulation of CYP26A1 expression by selective RAR and RXR agonists in human NB4 promyelocytic leukemia cells.
Idres N; Marill J; Chabot GG
Biochem Pharmacol; 2005 Jun; 69(11):1595-601. PubMed ID: 15896339
[TBL] [Abstract][Full Text] [Related]
25. all-trans-Retinoic acid-induced expression and regulation of retinoic acid 4-hydroxylase (CYP26) in human promyelocytic leukemia.
Ozpolat B; Mehta K; Tari AM; Lopez-Berestein G
Am J Hematol; 2002 May; 70(1):39-47. PubMed ID: 11994980
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic potential of the inhibition of the retinoic acid hydroxylases CYP26A1 and CYP26B1 by xenobiotics.
Nelson CH; Buttrick BR; Isoherranen N
Curr Top Med Chem; 2013; 13(12):1402-28. PubMed ID: 23688132
[TBL] [Abstract][Full Text] [Related]
27. Cytochrome P450s in the regulation of cellular retinoic acid metabolism.
Ross AC; Zolfaghari R
Annu Rev Nutr; 2011 Aug; 31():65-87. PubMed ID: 21529158
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and biological evaluation of 3-phenyl-3-aryl carboxamido propanoic acid derivatives as small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26A1).
Zhao D; Sun B; Ren J; Li F; Song S; Lv X; Hao C; Cheng M
Bioorg Med Chem; 2015 Mar; 23(6):1356-65. PubMed ID: 25684424
[TBL] [Abstract][Full Text] [Related]
29. Physiologically Based Pharmacokinetic Model of All-
Jing J; Nelson C; Paik J; Shirasaka Y; Amory JK; Isoherranen N
J Pharmacol Exp Ther; 2017 May; 361(2):246-258. PubMed ID: 28275201
[TBL] [Abstract][Full Text] [Related]
30. CYP26C1 Is a Hydroxylase of Multiple Active Retinoids and Interacts with Cellular Retinoic Acid Binding Proteins.
Zhong G; Ortiz D; Zelter A; Nath A; Isoherranen N
Mol Pharmacol; 2018 May; 93(5):489-503. PubMed ID: 29476041
[TBL] [Abstract][Full Text] [Related]
31. Scaling in vitro activity of CYP3A7 suggests human fetal livers do not clear retinoic acid entering from maternal circulation.
Topletz AR; Zhong G; Isoherranen N
Sci Rep; 2019 Mar; 9(1):4620. PubMed ID: 30874620
[TBL] [Abstract][Full Text] [Related]
32. Novel retinoic acid 4-hydroxylase (CYP26) inhibitors based on a 3-(1H-imidazol- and triazol-1-yl)-2,2-dimethyl-3-(4-(phenylamino)phenyl)propyl scaffold.
Gomaa MS; Bridgens CE; Illingworth NA; Veal GJ; Redfern CP; Brancale A; Armstrong JL; Simons C
Bioorg Med Chem; 2012 Jul; 20(14):4201-7. PubMed ID: 22727372
[TBL] [Abstract][Full Text] [Related]
33. Molecular targeting of retinoic acid metabolism in neuroblastoma: the role of the CYP26 inhibitor R116010 in vitro and in vivo.
Armstrong JL; Taylor GA; Thomas HD; Boddy AV; Redfern CP; Veal GJ
Br J Cancer; 2007 Jun; 96(11):1675-83. PubMed ID: 17486130
[TBL] [Abstract][Full Text] [Related]
34. Prospective teratology of retinoic acid metabolic blocking agents (RAMBAs) and loss of CYP26 activity.
McCaffery P; Simons C
Curr Pharm Des; 2007; 13(29):3020-37. PubMed ID: 17979744
[TBL] [Abstract][Full Text] [Related]
35. The relative importance of CYP26A1 in hepatic clearance of all-trans retinoic acid.
Thatcher JE; Zelter A; Isoherranen N
Biochem Pharmacol; 2010 Sep; 80(6):903-12. PubMed ID: 20513361
[TBL] [Abstract][Full Text] [Related]
36. Expression and functional characterization of cytochrome P450 26A1, a retinoic acid hydroxylase.
Lutz JD; Dixit V; Yeung CK; Dickmann LJ; Zelter A; Thatcher JE; Nelson WL; Isoherranen N
Biochem Pharmacol; 2009 Jan; 77(2):258-68. PubMed ID: 18992717
[TBL] [Abstract][Full Text] [Related]
37. Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice.
Patel JB; Huynh CK; Handratta VD; Gediya LK; Brodie AM; Goloubeva OG; Clement OO; Nanne IP; Soprano DR; Njar VC
J Med Chem; 2004 Dec; 47(27):6716-29. PubMed ID: 15615521
[TBL] [Abstract][Full Text] [Related]
38. Design and synthesis of substituted imidazole and triazole N-phenylbenzo[d]oxazolamine inhibitors of retinoic acid metabolizing enzyme CYP26.
Pautus S; Aboraia AS; Bassett CE; Brancale A; Coogan MP; Simons C
J Enzyme Inhib Med Chem; 2009 Apr; 24(2):487-98. PubMed ID: 18608743
[TBL] [Abstract][Full Text] [Related]
39. Novel tetralone-derived retinoic acid metabolism blocking agents: synthesis and in vitro evaluation with liver microsomal and MCF-7 CYP26A1 cell assays.
Yee SW; Jarno L; Gomaa MS; Elford C; Ooi LL; Coogan MP; McClelland R; Nicholson RI; Evans BA; Brancale A; Simons C
J Med Chem; 2005 Nov; 48(23):7123-31. PubMed ID: 16279770
[TBL] [Abstract][Full Text] [Related]
40. Homology model of human retinoic acid metabolising enzyme cytochrome P450 26A1 (CYP26A1): active site architecture and ligand binding.
Gomaa MS; Yee SW; Milbourne CE; Barbera MC; Simons C; Brancale A
J Enzyme Inhib Med Chem; 2006 Aug; 21(4):361-9. PubMed ID: 17059167
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
